Skip to content

Preliminary study on effect of high dose of Andrographis paniculata extract capsule in mild COVID-19 patients

Preliminary study on effect of high dose of Andrographis paniculata extract capsule in mild COVID-19 patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210914001
Enrollment
6
Registered
2021-09-14
Start date
2020-06-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in China. As of 18-May-2021, a total of 162.7 million cases COVID-19 cases with 434,796 and 3.3 million deaths have been reported globally. This pandemic disease is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 causes diseases ranging from common cold to severe disease. The common signs and symptoms of infection include fever, URI symptom as cough, runny

Interventions

The ethanolic extract of A. paniculata containing 20 mg of andrographolide in each capsule
Experimental Drug
Andrographis paniculata extract

Sponsors

Thai Traditional Medicine Knowlegde funding
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) age 18 to 60 years 2) diagnosis of SARS-CoV-2 infection by positive rRT-PCR test 3) being admitted to hospital within 72 hours of illness 4) presence of any signs and symptoms of mild COVID-19 (e.g., fever, cough, sore throat, malaise, headache, and diarrhea) 5) not having signs and symptoms of pneumonia or abnormal chest imaging

Exclusion criteria

Exclusion criteria: 1) Patient who be treated with any antiviral drugs i.e. favipiravir, remdesivir, Lopinavir, ritonavir, interferon (b1a), chloroquine or hydroxychloroquine 2) History of allergy to A. paniculata 3) Pregnancy or during lactation 4) Patient who has underlying medical conditions that increase risk of severe COVID-19 5) Patient with history of rheumatic heart disease and/or renal dysfunction due to Streptococcus group A 6) Patient who be treated with anticoagulants i.e., clopidogrel, warfarin, and aspirin.

Design outcomes

Primary

MeasureTime frame
symptom severity 5 days visual anolog scale,Adverse event 5 days number and severity of event

Secondary

MeasureTime frame
Inflamatory cytokines 5 days Bio-plex assay,metabolite profile 5 days LC-MS,viral load 5 days rt-pcr ct value calculation

Countries

Thailand

Contacts

Public ContactKulthanit Wanaratana

Department of Thai Traditional and Alternative Medicines, Thai Ministry of Public Health

kulthanitw@gmail.com66896336765

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026